It's time to revisit a company I haven't covered in quite a while. As the title of this article gave away, that company is ResMed (RMD), a fast-growing healthcare company. Since then, shares have ...

ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and ...

ResMed’s fiscal third quarter of 2025 results presented a mixed picture of the company’s financial health. The company reported revenue of $1.29 billion, representing a 9% year-over-year increase when ...